Highlights for the quarter ended 30 September 2017
• Revenue increased to US$1.2 million compared to US$0.2 million in Q3 2016; driven primarily by U.S. sales growth
• U.S. unit sales grew 108% compared to Q2 2017
• AeroForm® available in more than one hundred and twenty (120) hospitals across the US
• Third party contract manufacturer in Costa Rica validated and on-line for higher capacity production
• Closed US$15 million minimally-dilutive debt agreement with Oxford
• Cash and short-term investments balance as of 30 September 2017 of US$30.8 million
Palo Alto, CA, United States – AirXpanders, Inc. (ASX:AXP), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, today released its Appendix 4C – Quarterly Cash Flow report for the quarter ended 30 September 2017.
To view Report please download PDF attached:
Download this document
